Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review.

abstract：:Escitalopram is the (S)-enantiomer of the racemic selective serotonin reuptake inhibitor antidepressant citalopram. Clinical studies have shown that escitalopram is effective and well tolerated in the treatment of depression and anxiety disorders. Following oral administration, escitalopram is rapidly absorbed and rea...

journal_title：Clinical pharmacokinetics

authors： Rao N

更新日期：2007-01-01 00:00:00

abstract：OBJECTIVE:To study the pharmacokinetics of micafungin in intensive care patients and assess pharmacokinetic (PK) target attainment for various dosing strategies. METHODS:Micafungin PK data from 20 intensive care unit patients were available. A population-PK model was developed. Various dosing regimens were simulated: ...

journal_title：Clinical pharmacokinetics

authors： Martial LC,Ter Heine R,Schouten JA,Hunfeld NG,van Leeuwen HJ,Verweij PE,de Lange DW,Pickkers P,Brüggemann RJ

更新日期：2017-10-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Vicriviroc is a small-molecule CCR5 antagonist currently in development for the treatment of HIV in patients on a regimen containing a ritonavir-boosted protease inhibitor. As renal disease and renal dysfunction are prevalent in the HIV-infected population, patients with varying degrees of rena...

journal_title：Clinical pharmacokinetics

authors： Kasserra C,Sansone-Parsons A,Keung A,Tetteh E,Assaf M,O'Mara E,Marbury T

更新日期：2010-06-01 00:00:00

abstract：:Histamine H2-receptor antagonists are a unique class of compounds. Pharmacologically they are characterised as a family by their ability to inhibit the secretion of gastric acid, and kinetically they are classified as a family by their similarity in absorption, distribution and elimination. All the H2-receptor antagon...

journal_title：Clinical pharmacokinetics

authors： Lin JH

更新日期：1991-03-01 00:00:00

abstract：:Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) reduce hyperglycaemia by decreasing renal glucose threshold and thereby increasing urinary glucose excretion. They are proposed as a novel approach for the management of type 2 diabetes mellitus. They have proven their efficacy in reducing glycated haemoglobin...

journal_title：Clinical pharmacokinetics

authors： Scheen AJ

更新日期：2014-04-01 00:00:00

abstract：:The pharmacokinetic effect of extracorporeal elimination can be evaluated from the extracorporeal elimination rate constant, from the amount of drug removed, and from extracorporeal clearance. To compare the validity of these approaches in clinical practice, the effect of multiple plasma exchanges on the steady-state ...

journal_title：Clinical pharmacokinetics

authors： Keller F,Kreutz G,Vöhringer HF,Offermann G,Distler A

更新日期：1985-11-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Bosentan is a competitive antagonist on endothelin receptor A and B (ETA and ETB), displacing the endogenous binding partner endothelin-1 (ET-1) from its binding sites. After administration of escalating single doses of 10-750 mg as an intravenous (i.v.) infusion, bosentan showed dose-dependen...

journal_title：Clinical pharmacokinetics

authors： Volz AK,Krause A,Haefeli WE,Dingemanse J,Lehr T

更新日期：2017-12-01 00:00:00

abstract：:Measurement of drug levels is becoming increasingly popular to optimise the dosage of various drugs. In the case of antiarrhythmic drugs, the narrow therapeutic margin of most of these agents and a direct relationship between their pharmacological effects and plasma concentrations would justify more widespread use of ...

journal_title：Clinical pharmacokinetics

authors： Follath F,Ganzinger U,Schuetz E

更新日期：1983-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:This analysis used a population pharmacokinetic approach to identify covariates that influence plasma exposure of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management in overweight and obese individuals. METHODS:Samples for pharmacokinetic anal...

journal_title：Clinical pharmacokinetics

authors： Overgaard RV,Petri KC,Jacobsen LV,Jensen CB

更新日期：2016-11-01 00:00:00

abstract：:Data on the pharmacokinetics of ofloxacin in chronic renal failure, in patients who were not dialysed or were receiving haemodialysis or continuous ambulatory peritoneal dialysis (CAPD), are reviewed. In addition, a large pool of data obtained in patients with a wide range of renal dysfunction is provided. The good ab...

journal_title：Clinical pharmacokinetics

authors： Lameire N,Rosenkranz B,Malerczyk V,Lehr KH,Veys N,Ringoir S

更新日期：1991-11-01 00:00:00

abstract：:Antipsychotics may cause serious adverse cardiovascular effects, including prolonged QT interval and sudden death. This review considers antipsychotic-induced cardiovascular events from three perspectives: high-risk drugs, high-risk individuals and high-risk drug interactions. Pharmacokinetic drug interactions involvi...

journal_title：Clinical pharmacokinetics

authors： Brown CS,Farmer RG,Soberman JE,Eichner SF

更新日期：2004-01-01 00:00:00

abstract：:Consistent with its highest abundance in humans, cytochrome P450 (CYP) 3A is responsible for the metabolism of about 60% of currently known drugs. However, this unusual low substrate specificity also makes CYP3A4 susceptible to reversible or irreversible inhibition by a variety of drugs. Mechanism-based inhibition of ...

journal_title：Clinical pharmacokinetics

authors： Zhou S,Yung Chan S,Cher Goh B,Chan E,Duan W,Huang M,McLeod HL

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype. OBJECTIVE:To develop a population pharmacokinetic model for olmesartan (RNH-6270), the active metabolite of olmesartan medoxomil, in healthy volunteers and hypertens...

journal_title：Clinical pharmacokinetics

authors： Yoshihara K,Gao Y,Shiga H,Wada DR,Hisaoka M

更新日期：2005-01-01 00:00:00

abstract：:Etodolac is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is marked as the racemate. Currently, the drug is available in several countries for the treatment of arthritis and the alleviation of pain. Etodolac possesses several unique disposition features mainly due to its stereoselective pharmacokinetics. I...

journal_title：Clinical pharmacokinetics

authors： Brocks DR,Jamali F

更新日期：1994-04-01 00:00:00

abstract：:The effects of age and gender on the single and multiple dose pharmacokinetics of zileuton have been examined in a phase I nonblinded study. A total of 27 healthy volunteers were evaluable, 9 in the young group (age range 20 to 40 years; 5 males and 4 females) and 18 in the elderly group (range 65 to 81 years; 9 males...

journal_title：Clinical pharmacokinetics

authors： Braeckman RA,Granneman GR,Locke CS,Machinist JM,Cavannaugh JH,Awni WM

更新日期：1995-01-01 00:00:00

abstract：:Despite progress in the treatment of metastatic colorectal cancer (mCRC) in the last 15 years, it is still a condition with a relatively low 5-year survival rate. Panitumumab, a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR), is able to prolong survival in patients with mC...

journal_title：Clinical pharmacokinetics

authors： Ketzer S,Schimmel K,Koopman M,Guchelaar HJ

更新日期：2018-04-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Daclatasvir is a potent, pangenotypic once-daily hepatitis C virus (HCV) NS5A inhibitor that is approved for the treatment of chronic HCV infection. The objective of this analysis was to characterize the pharmacokinetics of daclatasvir in subjects with chronic HCV infection. METHODS:A populati...

journal_title：Clinical pharmacokinetics

authors： Chan P,Li H,Zhu L,Bifano M,Eley T,Osawa M,Ueno T,Hughes E,Bertz R,Garimella T,AbuTarif M

更新日期：2017-10-01 00:00:00

abstract：BACKGROUND:Fast-acting insulin aspart (faster aspart) is an ultra-fast-acting formulation of insulin aspart (IAsp). This post hoc analysis investigated the pharmacokinetics of faster aspart versus IAsp, measured as free or total IAsp, and the relationship between anti-IAsp antibodies and the pharmacokinetics/pharmacody...

journal_title：Clinical pharmacokinetics

authors： Haahr H,Pieber TR,Mathieu C,Gondolf T,Shiramoto M,Erichsen L,Heise T

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:Because of the vulnerability and frailty of elderly adults, clinical drug development has traditionally been biased towards young and middle-aged adults. Recent efforts have begun to incorporate data from paediatric investigations. Nevertheless, the elderly often remain underrepresented in clinical trials, e...

journal_title：Clinical pharmacokinetics

authors： Schlender JF,Meyer M,Thelen K,Krauss M,Willmann S,Eissing T,Jaehde U

更新日期：2016-12-01 00:00:00

abstract：:The results of research studies conducted to date in vitro and in healthy volunteers are practically all concordant in demonstrating the lack of any kind of interference between famotidine and microsomal oxidative metabolism. The pharmacokinetics (elimination half-life, area under the plasma concentration-time curve, ...

journal_title：Clinical pharmacokinetics

authors： Dal Negro R,Pomari C,Turco P

更新日期：1993-03-01 00:00:00

abstract：:The importance of in-depth knowledge about the pharmacokinetics of a drug is evident because pharmacokinetic behaviour may correlate with activity and toxicity. The most elaborate pharmacokinetic investigation is a so-called mass balance study employing a radioactive tracer. A mass balance study investigates the plasm...

journal_title：Clinical pharmacokinetics

authors： Beumer JH,Beijnen JH,Schellens JH

更新日期：2006-01-01 00:00:00

abstract：:Low-molecular-weight heparins are anticoagulants used in the treatment of thrombosis. They have effectiveness and safety profiles similar to those of unfractionated heparin but are considered an attractive alternative because of their predictable pharmacokinetic characteristics. In this article, we demonstrate the nee...

journal_title：Clinical pharmacokinetics

authors： Al-Sallami HS,Barras MA,Green B,Duffull SB

更新日期：2010-09-01 00:00:00

abstract：:In the treatment of patients with Parkinson's disease, apomorphine has an established place as a back-up therapy if other antiparkinsonian drugs, such as levodopa and oral dopamine agonists, have not controlled the existing response fluctuations. Apomorphine is a synthetic derivative of morphine, with a totally distin...

journal_title：Clinical pharmacokinetics

authors： Neef C,van Laar T

更新日期：1999-09-01 00:00:00

abstract：:This article reviews the information available to assist pharmacokineticists in the prediction of metabolic drug interactions. Significant advances in this area have been made in the last decade, permitting the identification in early drug development of dominant cytochrome P450 (CYP) isoform(s) metabolising a particu...

journal_title：Clinical pharmacokinetics

authors： Bertz RJ,Granneman GR

更新日期：1997-03-01 00:00:00

abstract：:Dilevalol and labetalol are examples of a growing number of new beta-blockers which combine nonselective beta-adrenoceptor antagonism with vasodilator activity. Dilevalol is one of the 4 stereoisomers of labetalol, and is estimated to form approximately 25% of the racemic drug. Labetalol itself is an alpha 1-antagonis...

journal_title：Clinical pharmacokinetics

authors： Donnelly R,Macphee GJ

更新日期：1991-08-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:To assess the influence of hepatitis C virus (HCV) co-infection and the extent of liver fibrosis on lopinavir/ritonavir pharmacokinetics in HIV-infected patients without liver function impairment. METHODS:Cross-sectional, comparative study enrolling HIV-infected adults receiving lopinavir/rito...

journal_title：Clinical pharmacokinetics

authors： Moltó J,Valle M,Blanco A,Negredo E,DelaVarga M,Miranda C,Miranda J,Domingo P,Vilaró J,Tural C,Costa J,Barbanoj MJ,Clotet B

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Pemetrexed is used for the treatment for non-small cell lung cancer and mesothelioma. Patients with renal impairment are withheld treatment with this drug as it is unknown what dose is well tolerated in this population. OBJECTIVE:The purpose of our study was to investigate the pharmacokinetics (PK) of pemet...

journal_title：Clinical pharmacokinetics

authors： de Rouw N,Boosman RJ,Huitema ADR,Hilbrands LB,Svensson EM,Derijks HJ,van den Heuvel MM,Burger DM,Ter Heine R

更新日期：2021-01-09 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Proprotein convertase subtilisin/kexin type 9 inhibition with monoclonal antibodies such as alirocumab significantly reduces low-density lipoprotein-cholesterol levels ± other lipid-lowering therapies. We aimed to develop and qualify a population pharmacokinetics (PopPK) model for alirocumab in...

journal_title：Clinical pharmacokinetics

authors： Djebli N,Martinez JM,Lohan L,Khier S,Brunet A,Hurbin F,Fabre D

更新日期：2017-10-01 00:00:00

abstract：:Clarithromycin is a semisynthetic macrolide antibiotic, structurally related to erythromycin. It has a more favourable pharmacokinetic profile than erythromycin, thus allowing twice-daily administration and possibly increasing compliance among outpatients. Clarithromycin is well absorbed from the gastrointestinal trac...

journal_title：Clinical pharmacokinetics

authors： Fraschini F,Scaglione F,Demartini G

更新日期：1993-09-01 00:00:00

abstract：:Creatine is a nonessential dietary component that, when supplemented in the diet, has shown physiological benefits in athletes, in animal-based models of disease and in patients with various muscle, neurological and neuromuscular disease. The clinical relevance of creatine supplementation is based primarily on its rol...

journal_title：Clinical pharmacokinetics

authors： Persky AM,Brazeau GA,Hochhaus G

更新日期：2003-01-01 00:00:00